With the 340B program taking punches from the drug industry almost daily, a bipartisan group of 84 Members of the U.S. House of Representatives and 29 Members of the U.S. Senate have placed themselves right in the program's corner. The letters were spearheaded by Sens. John Thune (R-S.D.) and Tammy Baldwin (D-Wis.) and Reps. Shelley Moore Capito (R-W.Va.) and Kathy Castor … [Read more...]
New Orphan Drug Rule Makes Sense
Last week, federal health officials published a final rule for the 340B drug discount program that enables rural hospitals to continue stretching their dollars, serving more patients, and improving their services. The July 23 regulation by the Health Resources and Services Administration (HRSA) implements statutory language that limited 340B drug discounts on orphan drugs for … [Read more...]
What Is 340B?
Congress created the 340B Drug Discount Program in 1992 to reduce outpatient prescription drug costs for safety net health care providers, enabling them to stretch scarce resources as far as possible, reaching more eligible patients and providing more comprehensive services. The program was enacted with strong bipartisan support from Congress and signed into law by President … [Read more...]
How Does 340B Work?
In the early 1990s, drug companies began raising prices sharply for safety net health care providers, partly in response to the Medicaid drug rebate program’s creation in 1990. Congress enacted 340B in 1992 to help ease some of this pressure on these providers. It said that, if a drug company wanted its products to continue to be eligible for Medicaid reimbursement, it would … [Read more...]
Is 340B Working?
Yes. Multiple reports show that safety net health care providers use 340B savings just as Congress intended: The Government Accountability Office (GAO) found in a September 2011 study that all 340B entities it interviewed reported using their 340B savings in ways that were consistent with the program’s intent. A June 2011 study by Safety Net Hospitals for Pharmaceutical … [Read more...]
Who Gains If 340B Is Restricted?
Many of those who say 340B should be restricted are the ones who will gain the most if that actually happens. Drug manufacturers and biotechnology companies have an obvious reason to restrict the program: They would get to keep more money. These companies are already making billions in profits. According to one recent study, the 11 biggest multinational drug companies racked … [Read more...]
If 340B Is Restricted, Who Loses?
Safety net hospitals, health centers, HIV/AIDS programs, specialized clinics—and the tens of millions of poor, uninsured, and underinsured patients who depend on them for free or inexpensive health care—would all lose if 340B is scaled back or terminated. … [Read more...]